PTEN and p53: Who will get the upper hand?

Mutations of *PTEN* and *p53* are very frequent, yet often mutually exclusive due to functional interdependence of the proteins and, according to a new study, the most intimate possible interaction: direct binding.

Tumor suppressor genes are conceptually regarded as autonomous anti-cancer units. Along this tenet, only their homozygous loss would lead to cancer pathogenesis (Knudson, 1971). At the cellular level, however, autonomy appears to be a remote concept since protein function and gene expression are well regulated through cooperating and antagonizing networks. Therefore, linking the regulatory mechanisms between tumor suppressors is key to understanding, predicting, and interfering with tumorigenesis. Given that previous work has demonstrated several layers of indirect crosstalk between the two most highly mutated tumor suppressors, p53 and PTEN, it would have certainly been tempting to speculate that PTEN also directly cooperates with p53 in tumor suppression. Mechanistically however, the role of PTEN in tumor suppression has been attributed to the cytoplasm while the site of action of p53 is definitely ascribed to the nucleus, thus rendering it problematic to envision how this would occur. According to a study published in this issue of *Cancer Cell* (Freeman et al., 2003), a direct functional crosstalk between PTEN and p53 does indeed exist, adding a novel twist to the emerging picture of the PTEN-p53 tumor suppressor network.

The p53 tumor suppressor acts as a transcription factor capable of regulating the expression of target genes critical for growth inhibition, cell senescence, and induction of apoptosis in response to DNA damage and oncogenic transformation (Sharpless and DePinho, 2002). Cells are therefore extremely sensitive to p53 levels and transcriptional activation. In the absence of stress, levels of p53 in normal cells are maintained low mostly through its constant proteasome-dependent degradation mediated by the mdm2 protein that acts as a p53 ubiquitin-ligase. A number of p53 posttranslational modifications that are subjected to a dynamic and tight regulation including phosphorylation, acetylation, and sumoylation lead to its stabilization and transcriptional activation upon cellular stress. The extraordinary multilayered complexity of the p53 regulatory network

and its central importance in tumor suppression make it an ideal molecular platform on which other tumor-suppressive pathways could impinge.

PTEN (for phosphatase and tensin homolog deleted on chromosome 10) mutations and partial or complete loss have been frequently reported in tumors of various histological origins. *PTEN* is also found mutated in three related human autosomal dominant disorders characterized by developmental defects and high tumor susceptibility (Di Cristofano and Pandolfi, 2000).

The *PTEN* gene encodes a dual specificity phosphatase, which to some surprise, however, has been shown to primarily dephosphorylate the plasma membrane lipid phosphatidyl-inositol-3-phosphate (PIP3) whereas examples of protein targets have remained rare. Conversion of PIP3 to PIP2, however, enables PTEN to effectively antagonize the PI3 kinase pathway, resulting in inactivation of the many PH domain-containing downstream protein kinases, most notably Akt and PDK1 (Cantley, 2002), which in turn act on a variety of proteins to stimulate cell survival, proliferation, growth, and migration.

In the mouse, complete *Pten* inactivation is embryonic lethal while *Pten* heterozygous mice co-develop, after a latency period, multiple tumors of various histological origins in complete agreement with an important and pleiotropic tumor suppressive role (Di Cristofano and Pandolfi, 2000). In *Pten* heterozygous mutants that have also lost one or both copies of the *p27^KIP1* gene, encoding a cell cycle inhibitor whose loss does not cause an overt cancer phenotype, *Pten*-specific tumors are markedly accelerated (Di Cristofano et al., 2001). Most notably, these tumors retain *Pten* expression, indicating that its tumor-suppressive function might be dose dependent, and Pten thus haploinsufficient in certain tissues in combination with loss of another tumor suppressor. These findings underscored the importance of establishing the regulatory mechanisms governing PTEN protein levels and activity as their tight regulation may be critical for tumor suppression.

The first report to link PTEN and p53

on a molecular level showed direct binding of p53 to a site in the *PTEN* promoter (Stambolic et al., 2001). On top of p53-independent basal expression, DNA-damaging events such as γ irradiation resulted in a p53-dependent increase of *PTEN* mRNA in several cell lines (Figure 1A, pathway 2). Moreover, in *Pten* null mouse embryonic fibroblasts (MEFs), p53-mediated apoptosis was impaired, underscoring the potential importance of *Pten* transactivation for this process. Altogether, this report positioned p53 upstream of *PTEN* in the regulation of its expression level.

However, it soon became apparent that PTEN could also regulate p53 function through its ability to antagonize PI3 kinase since Akt phosphorylation consensus sites were identified in mdm2, one of the major negative regulators of p53 (Mayo and Donner, 2001; Zhou et al., 2001). Upon phosphorylation of these sites, mdm2 translocated into the cell nucleus to ubiquitinate p53, resulting in its nuclear export and degradation. Since PTEN phosphatase activity is the major antagonist of Akt, it was therefore tempting to speculate that PTEN would prevent this p53 degradation pathway by keeping Akt inactive and that PTEN would therefore be an essential component of the p53 response upon DNA damage (Figure 1A, pathway 1). Indeed, the effect of PTEN on p53-mediated transcription was also soon reported (Mayo et al., 2002). PTEN, but not a phosphatase-dead mutant, was able to produce a moderate increase of p53-mediated transcription even in the presence of mdm2, indicating that PTEN by antagonizing PI3 kinase can indirectly protect p53 from the degradation pathway. Importantly, the above findings suggested that PI3 kinase inhibitors such as Wortmannin could sensitize refractory tumors with wt p53 to treatment with p53-inducing drugs such as etoposide by mimicking PTEN activity and thus increasing p53 stability (see Figure 1B).

In a study appearing in this issue of *Cancer Cell* (Freeman et al., 2003), the PTEN-p53 crosstalk is taken a step further by identifying a p53 binding domain in PTEN. By performing GST-pulldown

Figure 1. Functional crosstalk between PTEN and p53 and its therapeutic implications

A: PTEN and p53 interact on three levels.

1: The PTEN phosphatase inhibits activation of mdm2 by keeping Akt inactive. Akt, when activated through the PI3 kinase pathway, can phosphorylate cytoplasmic mdm2, resulting in its nuclear import. Nuclear mdm2 ubiquitinates p53 and targets it for proteasomal degradation in the cytoplasm.

2: DNA damage results in a sharp increase of p53 protein which, in turn, can enhance *PTEN* transcription by binding to the *PTEN* promoter leading to a positive feedback loop that protects p53 from degradation.

3: Pten binds to p53 resulting in increased p53 half-life. This interaction also stimulates p53-mediated transcription, although it is still unclear whether PTEN participates in a p53-DNA complex. Cytoplasmic PTEN may also antagonize p53 degradation by cytoplasmic proteasomes.

Active or inactive forms of enzymes are denoted by an "*a*" or "*i*" superscript, respectively.

B: Tumor cells can be resensitized to DNA damage-inducing agents.

Tumor cells can be incapable of a p53 response in spite of having the functional protein because loss of, e.g., PTEN function results in increased PI3 kinase activity. Thus, combination of DNA damage-inducing agents with PI3 kinase inhibitors can restore drug sensitivity.

experiments with p53 deletion mutants, the C terminus of p53 was found to bind PTEN. These in vitro binding studies could be confirmed by a series of co-immunoprecipitations in both human cell lines and in cells derived from a *Pten* conditional mouse knockout model. Intriguingly, on PTEN, the p53 binding activity was mapped to the C2 domain, which so far had only been implicated in stabilizing and properly positioning the catalytic phosphatase domain of PTEN at the plasma membrane (Georgescu et al., 2000; Lee et al., 1999). This finding led the authors to ask whether PTEN might regulate p53 activity independently of its enzymatic activity. The results indicate that phosphatase-dead mutants

of PTEN are capable of stabilizing p53 as well. In half-life experiments, catalytically inactive PTEN could even protect p53 from mdm2-independent degradation, indicating that it can counteract additional mechanisms aimed at degrading p53. In this respect, it could be speculated that PTEN can also compete with proteasomal degradation of p53 in the cytoplasm (Figure 1A, pathway 3). In human SAOS2 cells, it was furthermore observed that protection did not affect p53 mRNA levels, consistent with degradation occurring at the protein level. Next, the authors tested whether the interaction with PTEN might separately enhance p53-mediated transcription. In transcription transactivation assays adding back *PTEN* into *Pten* null MEFs, an increase in p53-mediated transcription could be observed in agreement with the previous findings by Mayo et al. However, in conflict with that report, add back of a phosphatase-dead PTEN mutant or the PTEN C2 domain only still resulted in some stimulation of p53 transactivation, consistent with a role for direct interaction in p53 stabilization. Given the multiple levels of crosstalk, it is not yet clear whether PTEN activates p53-mediated transcription per se in addition to protecting it from degradation. Also surprisingly, the study could be carried out in MEF cells that unexpectedly expressed high levels of p53, while usually such p53 levels have to be induced by DNA-damaging agents. Results obtained by electrophoretic mobility shift analysis left the question of a PTEN-p53 complex on DNA still open, while chromatin immunoprecipitation experiments using a p53 antibody and p21-specific primers confirmed the notion that transfection of PTEN independently of its enzymatic activity may result in an increase of p53 levels, hence potentiating its function. To assess the importance of Pten-p53 interactions in vivo, the authors made use of a compound mutant mouse model by crossing *Pten* and *p53* knock-

out mutant mice. They found that in a *p53* heterozygous background, the status of *Pten* was crucial since loss of just one allele of *Pten* dramatically accelerated tumor onset to the rate observed in *p53* null mice. Although mutations of the remaining *p53* and *Pten* alleles were not formally excluded, these preliminary results are in agreement with the author's observations in murine cell lines. In summary, compelling experimental evidence unraveling an intimate functional crosstalk between PTEN and p53 has been accrued in the past two years. These findings are in agreement with a recent observation made in human breast cancers, demonstrating that *PTEN* and *p53* somatic mutations are mutually exclusive and do not occur in the same compartment (stroma versus epithelium) or in the same sample (Kurose et al., 2002).

The study by Wu and colleagues raises many important questions. It is not presently clear how much a direct interaction with PTEN contributes to p53 stabilization, nor is it known how PTEN binding would lead to p53 stabilization. It would also be interesting to determine whether p53 modifications such as phosphorylation or ubiquitination affect it or if, in turn, PTEN binding regulates these posttranslational modifications. If PTEN interacts with p53 in the cytoplasm (Figure 1A, pathway 3) and whether this regulates p53 nuclear import need also to be assessed. This is of particular relevance in view of the recent identification of proteins such as PARC that actively anchor p53 in the cytoplasm in the absence of cellular stress (Nikolaev et al., 2003). It also remains to be determined to what extent p53-mediated apoptosis depends on a direct PTEN-p53 interaction. To this end, it will be important to study whether cancer-associated mutations of *PTEN* or *p53* specifically interfere with their interaction, which would firmly establish the relevance of the novel finding to human disease.

Lloyd C. Trotman and
Pier Paolo Pandolfi*

Molecular Biology Program and
Department of Pathology
Sloan-Kettering Institute
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, New York 10021
*E-mail: p-pandolfi@ski.mskcc.org

Selected reading

Cantley, L.C. (2002). Science *296*, 1655–1657.

Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P.P. (2001). Nat. Genet. *27*, 222–224.

Di Cristofano, A., and Pandolfi, P.P. (2000). Cell *100*, 387–390.

Freeman, D.J., Li, A.G., Wei, G., Li, H.-H., Kertesz, N., Lesche, R., Whale, A.D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R.D., et al. (2003). Cancer Cell *3*, this issue, 117–130.

Georgescu, M.M., Kirsch, K.H., Kaloudis, P., Yang, H., Pavletich, N.P., and Hanafusa, H. (2000). Cancer Res. *60*, 7033–7038.

Knudson, A.G., Jr. (1971). Proc. Natl. Acad. Sci. USA *68*, 820–823.

Kurose, K., Gilley, K., Matsumoto, S., Watson, P.H., Zhou, X.P., and Eng, C. (2002). Nat. Genet. *32*, 355–357.

Lee, J.O., Yang, H., Georgescu, M.M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J.E., Pandolfi, P., and Pavletich, N.P. (1999). Cell *99*, 323–334.

Mayo, L.D., Dixon, J.E., Durden, D.L., Tonks, N.K., and Donner, D.B. (2002). J. Biol. Chem. *277*, 5484–5489.

Mayo, L.D., and Donner, D.B. (2001). Proc. Natl. Acad. Sci. USA *98*, 11598–11603.

Nikolaev, A.Y., Li, M., Puskas, N., Qin, J., and Gu, W. (2003). Cell *112*, 29–40.

Sharpless, N.E., and DePinho, R.A. (2002). Cell *110*, 9–12.

Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., and Mak, T.W. (2001). Mol. Cell *8*, 317–325.

Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M.C. (2001). Nat. Cell Biol. *3*, 973–982.

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

Daniel J. Freeman,[1,5] Andrew G. Li,[3,5] Gang Wei,[3] Heng-Hong Li,[3] Nathalie Kertesz,[1] Ralf Lesche,[1,6] Andrew D. Whale,[3] Hilda Martinez-Diaz,[1] Nora Rozengurt,[2] Robert D. Cardiff,[4] Xuan Liu,[3,*] and Hong Wu[1,*]

[1]Howard Hughes Medical Institute, Department of Molecular and Medical Pharmacology
[2]Department of Pathology and Laboratory Medicine
UCLA School of Medicine, Los Angeles, California 90095
[3]Department of Biochemistry, University of California, Riverside, California 92521
[4]Department of Pathology, Center for Comparative Medicine, University of California, Davis, California 95616
[5]These two authors contributed equally.
[6]Present address: Epigenomics AG, Kastanienallee 24, 10435 Berlin, Germany.
*Correspondence: hwu@mednet.ucla.edu (H.W.), xuan.liu@ucr.edu (X.L.)

Summary

We show in this study that PTEN regulates p53 protein levels and transcriptional activity through both phosphatase-dependent and -independent mechanisms. The onset of tumor development in $p53^{+/-};Pten^{+/-}$ mice is similar to $p53^{-/-}$ animals, and p53 protein levels are dramatically reduced in $Pten^{-/-}$ cells and tissues. Reintroducing wild-type or phosphatase-dead PTEN mutants leads to a significant increase in p53 stability. PTEN also physically associates with endogenous p53. Finally, PTEN regulates the transcriptional activity of p53 by modulating its DNA binding activity. This study provides a novel mechanism by which the loss of PTEN can functionally control "two" hits in the course of tumor development by concurrently modulating p53 activity.

Introduction

PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene was the first phosphatase identified to be frequently mutated/deleted somatically in various human cancers (Li et al., 1997, 1998; Steck et al., 1997). In addition, germline mutations in the *PTEN* gene have been associated with Cowden syndrome and related diseases in which patients develop hyperplastic lesions (harmatomas) in multiple organs with increased risks of malignant transformation (Liaw et al., 1997; Marsh et al., 1998; Nelen et al., 1997). PTEN contains a sequence motif that is highly conserved in the members of the protein tyrosine phosphatase family. PTEN has been shown to possess phosphatase activity on phosphotyrosyl and phosphothreonyl-containing substrates (Li et al., 1998; Myers and Tonks, 1997) in vitro and on phosphatidylinositol (3,4,5) trisphosphate, a product of phosphatidylinositol 3-kinase (PI3K), both in vitro and in vivo (Lee et al., 1999; Maehama and Dixon, 1998; Myers et al., 1998; Stambolic et al., 1998; Sun et

al., 1999). Many cancer-related mutations have been mapped within the conserved catalytic domain of PTEN, suggesting that the phosphatase activity of PTEN is required for its tumor suppressor function. In addition to its phosphatase domain, PTEN also contains a putative C2 regulatory domain, a PIP2 binding motif, two PEST homology regions, and a consensus PDZ binding site. The functions of these structural domains include regulating the phosphatase activity and controlling the stability or subcellular localization of PTEN (Maehama et al., 2001). Disruption of the murine *Pten* locus further supports the importance of PTEN as a bona fide tumor suppressor (Di Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998). Homozygous deletion of *Pten* results in early embryonic lethality. *Pten* heterozygous mice develop hyperplastic/neoplastic changes in multiple organs as early as 4 weeks, with a bias toward incidence in lymphoid, endometrial, mammary, gastrointestinal, and adrenal gland tissues (Podsypanina et al., 1999; Suzuki et al., 1998).

The major function of the tumor suppressor PTEN relies on its phosphatase activity and subsequent antagonism of the

---

S I G N I F I C A N C E

It has been shown by many groups, including our own, that the major function of the PTEN tumor suppressor relies on its phosphatase activity by antagonizing the PI3K/AKT pathway. This study provides evidence that PTEN can modulate p53 function independently of its phosphatase activity, and that a physical interaction between PTEN and p53 is important for this modulation in vivo. We also provide in vivo evidence for PTEN's function inside of the nucleus. Consequently, our study provides a novel mechanism by which PTEN regulates p53 levels and activities, and possibly provides an avenue for targeted therapy for cancers caused by PTEN or p53 loss.

PI3K/AKT pathway (Di Cristofano and Pandolfi, 2000; Maehama et al., 2001; Simpson and Parsons, 2001). Loss of PTEN function, either in murine embryonic stem cells or in human cancer cell lines, results in accumulation of PIP3 and activation of its downstream effectors, such as AKT/PKB (Franke et al., 1997; Stambolic et al., 1998; Sun et al., 1999; Wu et al., 1998). As a serine/threonine protein kinase, AKT functions by phosphorylating key intermediate signaling molecules, leading to increased cell metabolism, cell growth, cell survival, and cell invasiveness—all hallmarks of cancer (for review, see Downward, 1998; Hanahan and Weinberg, 2000; Hill and Hemmings, 2002). Genetic studies also indicate that AKT plays an essential role in PTEN-controlled signal transduction and tumorigenesis (Stiles et al., 2002; Stocker et al., 2002).

Recent studies suggest that there is a tight link between PTEN and p53, another major tumor suppressor. Both PTEN and p53 regulate cell proliferation and cell death (for review, see Bargonetti and Manfredi, 2002; Yamada and Araki, 2001). Even though *PTEN* and *p53* are frequently mutated in both inherited and spontaneous tumors in humans, concomitant mutations in both *p53* and *PTEN* loci are not common (Kurose et al., 2002; Fujisawa et al., 2000; Kato et al., 2000; Koul et al., 2002; Rasheed et al., 1997). Several commonly used human *PTEN* null tumor cell lines, such as U87 MG, 786-O, MCF-7, and LNCap, are wild-type for *p53*. These genetic observations suggest that loss of *PTEN* may reduce the selective pressure on tumors during cancer progression to lose *p53*. Mechanistically, several lines of evidence suggest that PTEN-controlled AKT activation plays an essential role in modulating MDM2-dependent p53 degradation (for review, see Mayo and Donner, 2002; Zhou and Hung, 2002. p53 is a short-lived protein and stabilization of p53 is crucial for its tumor suppressor function. The p53 protein is maintained at low levels in normal cells by MDM2-mediated ubiquitination and subsequent proteolysis. AKT physically associates with MDM2 and phosphorylates MDM2 on serine residues, a key step involved in MDM2 nuclear translocation and MDM2-mediated p53 degradation (Mayo and Donner, 2001; Ogawara et al., 2002; Zhou et al., 2001). Therefore, it is conceivable that activation of AKT in PTEN-deficient cells may cause more rapid p53 degradation, which could contribute to tumorigenesis caused by PTEN loss. Furthermore, p53 can bind to the PTEN promoter region and activate PTEN transcriptionally (Stambolic et al., 2001), although there is a debate about the significance of such regulation (Sheng et al., 2002).

To test the functional significance of the crosstalk between PTEN and p53 in vivo, we employed a genetic approach to study tumorigenesis in $Pten^{+/-};p53^{+/-}$ compound heterozygous mice on a 129/Balb/c genetic background. We found that the onset of lymphoma development in $p53^{+/-};Pten^{+/-}$ mice is similar to that seen in $p53^{-/-}$ animals. To further investigate the link between PTEN and p53, we demonstrated that p53 protein levels are dramatically reduced in $Pten^{-/-}$ cells and that PTEN stabilizes p53 by increasing its half-life. Furthermore, ectopic expression of PTEN phosphatase-dead mutants also leads to a significant increase in p53 protein levels, and PTEN can stabilize p53, even in the absence of MDM2, suggesting that PTEN can regulate p53 levels in a phosphatase-independent and MDM2-independent manner. Significantly, we observe that PTEN physically associates with endogenous p53, and PTEN regulates the transcriptional activity of p53 by modulating its DNA binding. Thus, PTEN-p53 may represent a self-reinforced circuit impor-tant for maintaining normal cellular functions, and disruption of this circuit may lead to cancer formation.

Results

PTEN and p53: A genetic study

We have generated a *Pten*-deficient mouse line by homologous recombination via embryonic stem cells (ES cells). Similar to previous reports, mice lacking PTEN died early during embryogenesis, and mice with heterozygous *Pten* deletion developed tumors in various tissues (Figure 1A). However, the consequences of *Pten* inactivation on a 129/Balb/c genetic background are quite different from what was reported on a 129/C57 background (R. Lesche et al., submitted). In particular, most of the heterozygous mice are tumor free for the first six months of their postnatal life: 10% of $Pten^{+/-}$ animals developed focal lymphoid hyperplasia in the thymus and enlarged lymph nodes near the neck and axilla (Figure 1A, left). Among aged animals (7–14 months), 25% of them developed lymphoid hyperplasia/dysplasia (Figure 1A, right) and 10% of those progressed to early lymphoblastic lymphoma of T cell origin, similar to previous reports (Podsypanina et al., 1999; Suzuki et al., 1998).

This prolonged latency in tumor development provided us with a unique opportunity to genetically evaluate the possible interaction between PTEN and p53. We generated mice heterozygous for both *p53* and *Pten* (compound heterozygous, $p53^{+/-};Pten^{+/-}$) on the 129/Balb/c background and followed a cohort of compound heterozygous animals (n = 33; male: female = 14:19) for six months. Seven $p53^{+/-};Pten^{+/-}$ mice died between 2–6 months of age. The rest of the animals were subjected to pathological analysis upon tumor development from as early as 1 month of age. As shown in Figure 1B, the onset (left panel) and lymphoma (right panel) development in the $p53^{+/-};Pten^{+/-}$ mice are very similar to those of $p53^{-/-}$ (n = 23) mice, but differ significantly from mice heterozygous for $p53$ (Macleod and Jacks, 1999) and for *Pten* (Figure 1A). Similarly to what was reported in $p53^{-/-}$ animals, $p53^{+/-};Pten^{+/-}$ mice develop lymphomas preferentially in the lymph nodes. As shown in Figure 1C, the enlarged lymph nodes are tightly packed with a dense population of homogeneous small lymphocytes with a few scattered germinal centers. Immunohistochemical staining using anti-CD3 antibody reveals nodules of uniform, atypical, immature T cells in the peri-follicular zones, suggesting early lymphoblastic lymphoma of T cell origin. The majority of these samples have well-defined cortex and medullary with some highly vascularized areas. In 40% of cases, neoplastic lymphocytes are packed in the vessels and have infiltrated the surrounding tissues (data not shown).

To ensure that the initiation of tumor development in $p53^{+/-};Pten^{+/-}$ mice is not due to the loss of the second allele of either the *Pten* or *p53* gene (loss of heterozygosity, LOH), immunohistochemical (IHC) analysis was performed on the tumors derived from the compound heterozygous ($p53^{+/-};Pten^{+/-}$) mice. Figure 2A shows that PTEN protein is present in these tumors (lower left) at levels similar to adjacent normal tissues (lower right) and comparable to those of $Pten^{+/-}$ mice (upper left). However, p53 is expressed at basal levels in most of the tissues and tumor samples and cannot be detected by conventional IHC analysis (data not shown). Thus, we conducted PCR and Western blot analysis. The second alleles of *Pten* and *p53* are retained in the tumor samples (Figure 2B),

Figure 1. Tumor development in *Pten*[+/−] and compound heterozygous *p53*[+/−];*Pten*[+/−] mice

A: Tumor onset curve (left panel) and spectra (right panel) show the tumor susceptibility in *Pten*[+/−] mice on the 129/Balb/c background.

B: Tumor onset curve shows that the tumor susceptibility in *p53*[+/−];*Pten*[+/−] mice is greatly enhanced over *p53* or *Pten* heterozygous mice but similar to *p53*[−/−] mice (left panel); the incidence of lymphoma formation in the compound heterozygous animals is also similar to that of the p53 null mice (right panel).

C: Low magnification images showing an early lymphoblastic lymphoma in a lymph node; left, H/E staining showing the architecture; middle, B220-positive staining B cells; and right, CD3-positive stained T cells. Note that the central mass of the immature cells is most positive for CD3. Bar = 200 μM.

and a substantial amount of p53 protein can also be detected in these tumors using an antibody that recognizes both WT and mutated form of p53 (Pab-240, Figure 2C, upper panel). To ensure that WT p53 is present in the mutant sample, we conducted IP-Western blot analysis using an antibody that only reacts with WT p53 (Pab-246, Figure 2C, lower panel). It appears, from this study, that WT p53 is present in the tumor samples. These results lead to our conclusion that LOH is not required for the initiation of tumor development in these compound heterozygous mice. However, we cannot exclude (1) loss of function mutations in either the *p53* or *Pten* genes which cannot be detected by our assay systems; (2) localized or single cell-based allelic deletion or gene silencing events; and (3) that LOH is involved in or associated with tumor progression and local invasion.

PTEN modulates p53 protein stability

To investigate whether PTEN indeed controls p53 function in vivo, we first measured endogenous p53 mRNA and protein levels in isogenic *Pten*[+/+], *Pten*[+/−], and *Pten*[−/−] ES cells. p53 protein levels are significantly reduced in *Pten* heterozygous ES cells and almost completely lost in *Pten* null ES cells (Figure 3A, upper panel), while these ES cells do express similar levels of p53 mRNA (Figure 3A, lower panel), suggesting that PTEN modulates p53 at the posttranscriptional level. To confirm that PTEN is capable of controlling p53 protein levels in vivo and to prove that this regulation is a common mechanism rather than a cell type-specific event, we measured p53 levels in brain tissues derived from *Pten* conditional knockout mice (Groszer et al., 2001). Similarly to ES cell studies, p53 levels are reduced in heterozygous animals and almost completely lost in *Pten* null brains (Figure 3B). To develop a system that is amenable to

A

PTEN IHC x20

Pten⁺/⁻ (upper left)

Pten⁻/⁻ (upper right)

P53⁺/⁻;Pten⁺/⁻ (lower left)

P53⁺/⁻;Pten⁺/⁻ (lower right)

Figure 2. The presence of PTEN and p53 in lymphomas generated from compound heterozygous $p53^{+/-};Pten^{+/-}$ mice

A: Immunohistochemical detection of PTEN protein. Positive signal can be detected in the brain tissue of $Pten^{+/-}$ heterozygous mice (upper left), the lymphoma sample of $p53^{+/-};Pten^{+/-}$ compound heterozygous mice (lower left), the normal mammary gland adjacent to the lymphoma seen in the lower left (lower right), but not in the brain tissues from brain-specific $Pten$ deletion mice (Groszer et al., 2001).

B: PCR analysis of tail DNA and tumor DNA from representative $p53^{+/-};Pten^{+/-}$ compound heterozygous mice, indicating the presence of the WT alleles of both $p53$ and $Pten$ genes.

C: Upper panel, Western blot analysis using anti-p53 antibody (Pab 240, Santa Cruz technology). p53 proteins are present in the representative tumor samples of $p53^{+/-};Pten^{+/-}$ compound heterozygous mice; lower panel, cell lysate from the tumor tissue was immunoprecipitated with an anti-p53 antibody which specifically reacts to the WT p53 protein (Pab 246, Santa Cruz Biotechnology) and immunoblotted with Pab 240 antibody.

B


C

IB: α-p53 (PAb240)

biochemical analysis, we generated several isogenic mouse embryonic fibroblast (MEF) lines, which are wild-type for $p53$ but differ in their $Pten$ status, first by immortalizing MEF cells from $Pten$ conditional knockout mice (Lesche et al., 2002), $Pten^{loxp/loxp}$ (functional equivalent to WT [L/L]), and then by confirming PTEN and p53 expression by Northern and Western blot analyses (data not shown). Immortalized $Pten^{loxp/loxp}$ lines, which contain both p53 and PTEN protein products, were treated transiently with Cre recombinase. Three independent clones, which carry a homozygous $Pten$ deletion (Figure 3C, upper panel; $Pten^{\Delta loxp/\Delta loxp}$, functional equivalent to null mutant [Δ/Δ]) but are wild-type for p53, were generated and used for studies described below. Similar to our analysis using ES cells and brain tissues, p53 protein levels, but not mRNA levels, were significantly reduced in $Pten^{\Delta loxp/\Delta loxp}$ MEF cells (Figure 3C).

To determine the cause of the reduced p53 protein levels in $Pten$ null cells and tissues, we measured the half-life of p53 in $Pten^{loxp/loxp}$ and $Pten^{\Delta loxp/\Delta loxp}$ MEF cells. Notably, the half-life of p53 in $Pten^{loxp/loxp}$ MEF cells was significantly longer than in $Pten^{\Delta loxp/\Delta loxp}$ MEF (17 min versus 6 min, Figure 3D), providing genetic evidence that PTEN controls endogenous p53 protein levels by modulating its protein stability. Interestingly, the half-life of p53 falls in between WT and $Pten$ null cells (12 min) when $Pten^{\Delta loxp/\Delta loxp}$ MEF cells are pre-treated with wortmannin, a PI3 kinase inhibitor (see Supplemental Data at http://www.cancercell.org/cgi/content/full/3/2/117/DC1), suggesting that PTEN may control p53 protein levels via both PI3 kinase/AKT-dependent and -independent mechanisms.

PTEN affects p53 protein stability: phosphatase and MDM2-independent mechanisms

In order to determine whether reduced p53 stability in $Pten$ null cells and tissues is due to a PTEN phosphatase-independent activity, we reintroduced either wild-type or $PTEN$ phosphatase-dead mutants into the $Pten^{\Delta loxp/\Delta loxp}$ MEF cells. As shown in Figure 4A, reintroducing WT $PTEN$ led to a significant increase in p53

Figure 3. PTEN controls p53 protein stability

p53 protein levels in (**A**) ES cells and (**B**) brain tissues with different *Pten* status, indicating that PTEN regulates p53 protein posttranscriptionally.
C: PTEN regulates p53 protein levels in isogenic MEF cell lines (upper panel). The absence of *Pten* gene expression and presence of *p53* mRNA in *Pten*$^{\Delta loxp/\Delta loxp}$ MEFs are demonstrated by Northern blot analysis (lower panel).
**D:** PTEN controls p53 half-life. *Pten*$^{loxp/loxp}$ and *Pten*$^{\Delta loxp/\Delta loxp}$ MEF cells were cultured to 70% confluence before being transferred to serum free medium containing 50 µg/ml cyclohexamide. Cells were directly lysed at the indicated time points and p53 proteins were detected by Western blot analysis. The half-life of p53 protein in the presence (first row) and absence (second row) of endogenous PTEN proteins were calculated using Quantity One (Bio-Rad).

protein levels (comparing lanes 2 and 3). Interestingly, two phosphatase-dead mutants, *PTEN*-CS and *PTEN*-GR, as well as the PTEN-C2 domain alone, were also able to increase p53 protein levels, even though they did not affect AKT phosphorylation, a hallmark of PTEN's phosphatase activity (Figure 4A, comparing lane 3 with lanes 4–6). We further tested the abilities of wild–type or *PTEN-CS* to modulate human p53 protein levels using *p53* null human osteosarcoma SAOS2 cells. Again, both the WT and *PTEN-CS* mutants led to a 5- to 6-fold increase in transfected p53 protein levels but not its mRNA levels (Figure 4B). These data suggest that (1) PTEN controls p53 protein levels in both human and murine cells; and (2) PTEN controls p53, at least in part, by a mechanism independent of its phosphatase activity.

The control of p53 protein levels is orchestrated by multiple factors with MDM2 being one of the major players. Thus, it is not surprising that increased AKT activity in *Pten*-deficient cells will lead to increased MDM2 phosphorylation and nuclear translocation, resulting in p53 degradation. Similar to previous reports, MDM2 nuclear translocation is indeed increased in our *Pten*$^{\Delta loxp/\Delta loxp}$ cells (see Supplemental Data on Cancer Cell website). However, the MDM2-dependent pathway is probably not

the only mechanism by which PTEN can control p53. The fact that the *PTEN* phosphatase-dead mutants could regulate p53 levels (Figures 4A and 4B) suggests that PTEN can control p53 by multiple mechanisms, one of which does not require its phosphatase activity and thus may be MDM2 independent. To genetically prove that PTEN can control p53 in a MDM2-independent manner, we took advantage of a *p53*$^{-/-}$*;Mdm2*$^{-/-}$ MEF cell line. As illustrated in Figure 4C, the expression of PTEN led to a near 7-fold increase in p53 protein levels in the absence of MDM2 (Figure 4C, lanes 1 and 2). Furthermore, PTEN expression could partially prevent p53 degradation caused by overexpression of MDM2 (Figure 4C, lanes 3 and 4). To further investigate the mechanism involved in MDM2-independent p53 stabilization by PTEN, we measured the half-life of p53 in *p53*$^{-/-}$*;Mdm2*$^{-/-}$ MEF cells by transfecting p53 with and without *PTEN*. The half-life of p53 is significantly prolonged in the *PTEN* co-transfected cells (15 hr; Figure 4D, +PTEN), as compared to p53 alone (10 hr; Figure 4D, −PTEN). Again, PTEN-CS mutant had similar effect on p53 protein levels (see Supplemental Data at http://www.cancercell.org/cgi/content/full/3/2/117/DC1). How PTEN modulates p53 half-life in the absence of MDM2

Figure 4. PTEN controls p53 protein levels through phosphatase and MDM2-dependent and –independent mechanisms

A: Wild-type and phosphatase-dead *PTEN* mutants can rescue p53 protein levels in *Pten*$^{\Delta loxp/\Delta loxp}$ MEF cells. Cell lysates were analyzed by immunoblotting with Pab-240 p53 antibody, phospho-Akt (Ser473) antibody, and Akt antibody, respectively.

B: Co-transfection of p53 with either PTEN-WT or PTEN-CS mutant in p53 null human SAOS2 leads to increased p53 protein levels. Western blot was immunoblotted with p53 antibody (D0-1, upper panel); lower panel, RT-PCR analysis indicates no difference in p53 mRNA levels.

C: PTEN controls p53 protein levels by an MDM2-independent mechanism. *p53*$^{-/-}$;*MDM2*$^{-/-}$ MEF cells were transfected with vectors expressing: p53 alone (lane 1), p53 and PTEN (lane 2), p53 and MDM2 (lane 3), or p53/MDM2/PTEN (lane 4). Cell lysates were analyzed by immunoblotting with p53, PTEN, and MDM2 antibodies, respectively. The Western blots were quantified (Quantity One, Bio-Rad) and the fold of increase is presented on the top of each row as compared to the first lane.

D: PTEN controls p53's half-life by an MDM2-independent mechanism. *p53*$^{-/-}$;*MDM2*$^{-/-}$ MEF cells were transfected with a control or PTEN expression vector. Twenty-four hours post transfection, the cells were transferred to serum free medium containing 50 μg/ml cyclohexamide. Cells were directly lysed at the indicated time points.

is currently unknown and is worth further investigation. Taken together, the data indicate that PTEN can control p53 stability by both phosphatase and MDM2-dependent and -independent mechanisms.

**PTEN physically interacts with p53 and forms a PTEN/ p53 complex in the absence of MDM2**

We then tested whether PTEN controls p53 by physically associating with p53. Cell lysates from *Pten*$^{loxp/loxp}$ (*L/L*) or *Pten*$^{\Delta loxp/\Delta loxp}$ (Δ/Δ) lines were immunoprecipitated and Western blotted with either an anti-PTEN or an anti-p53 antibody, respectively. Endogenous PTEN and p53 can reciprocally co-immunoprecipi-

tate each other in vivo in the *Pten*$^{loxp/loxp}$ cells while no PTEN/ p53 complex formation could be detected in *Pten*$^{\Delta loxp/\Delta loxp}$ cells (Figure 5A, left panels). To determine whether PTEN, p53, and MDM2 were in the same complex, we re-probed the blots with anti-MDM2 antibody and found that MDM2 is not in the PTEN/ p53 complex (Figure 5A, upper right panel). Cell fractionation studies indicate that the majority of the PTEN/p53 complex is present in the nucleus (Figure 5A, lower right panel). Similarly, endogenous PTEN can physically associate with p53 in U2OS cells (Figure 5B). Using various GST fusion proteins, we further mapped regions crucial for PTEN-p53 interaction to the carboxy-terminal regulatory domain of p53 (R domain, amino acids

A

MEF Cells

B

U2OS Cells

Figure 5. Endogenous PTEN and p53 can physically form a complex in vivo

A: Left panels, PTEN and p53 reciprocally immunoprecipitate each other in the *Pten$^{loxp/loxp}$* WT MEF cells (first lanes), but not in *Pten$^{\Delta loxp/\Delta loxp}$* null MEFs (second lanes). Since anti-PTEN antibody used here is a polyclonal antibody and PTEN migrates close to the IgG band, there is a trace amount of background signal present in the Δ/Δ lane as well as IgG lane; right upper panel, Immunoblot from left panels was re-probed with MDM2 antibody and indicate that MDM2 is not in the PTEN/p53 complex. Right lower panel shows the PTEN/p53 complex formation in the nucleus. Nuclear (N) but not cytoplasmic (C) fractions. The cell lysates from the *Pten$^{loxp/loxp}$* (first two lanes) and *Pten$^{\Delta loxp/\Delta loxp}$* null MEFs (last two lanes) were immunoprecipitated with anti-PTEN antibody and Western blot was probed with anti-p53 antibody. A portion of each fraction before immunoprecipitation was run on an SDS-PAGE, and resulting Western blot was probed with anti-HDAC and anti-Actin antibodies as a controls.

B: Endogenous PTEN complexes with human p53 in U2OS cells. Untreated sub-confluent U2OS whole-cell lysates were used for immunoprecipitation (left panel). The supernatant is shown as a control (right panel).

363–393; Figure 6A) and to the C2 domain of PTEN, which does not include any part of the PTEN phosphatase domain (Figure 6B).

PTEN controls the transcriptional activity of p53

To test the functional significance of the PTEN and p53 association, we investigated whether PTEN could influence p53 transcriptional activity. p53 transcriptional activity is reduced by at least 50% in *Pten$^{\Delta loxp/\Delta loxp}$* cells (Figure 7A, left panel). To separate PTEN's role in enhancing p53 stability from increasing p53 transcriptional activity, *Pten$^{\Delta loxp/\Delta loxp}$* (Δ/Δ) and *Pten$^{loxp/loxp}$* (L/L) cells

were treated without or with leptomycin B (LMB), a nuclear export inhibitor that can prevent p53 from degradation (Freedman and Levine, 1998). LMB treatment rescued p53 protein in *Pten$^{\Delta loxp/\Delta loxp}$* (Δ/Δ) cells to a level comparable to the control cells (Figure 7A, right panel), providing additional evidence that PTEN controls p53 protein levels by preventing p53 from degradation. However, LMB treatment could not restore the transcriptional activity of p53 in *Pten$^{\Delta loxp/\Delta loxp}$* cells (Figure 7A, left panel), indicating that the physical interaction between PTEN and p53 is essential for maximizing p53's transcriptional activity. Overexpression of WT PTEN in either *Pten$^{loxp/loxp}$* (L/L) or *Pten$^{\Delta loxp/\Delta loxp}$* (Δ/Δ)

Figure 6. Mapping PTEN-p53 association domains

A: The WT as well as p53 N-terminal and C-terminal deletion mutants (shown in middle left panel) were in vitro translated and tested for binding to GST-PTEN-WT (lanes 7 to 9) or GST-PTEN-CS (lanes 10 to 12).

B: The WT and PTEN deletion mutants (shown in middle right panel) were expressed as GST fusion proteins and binding of p53 was measured by incubation with in vitro translated p53 or p53-ΔC mutant proteins. The interaction data were quantified, relative to the 10% input shown in the first lane, for both p53 (**A**) and PTEN (**B**).

cells led to comparable increases in p53 transcriptional activity (Figure 7B), demonstrating that the reduced p53 transcriptional activity in *Pten* null cells is not due to mutations in the *p53* gene. Interestingly, expression of either *PTEN-CS* phosphatase-dead mutant or the C2 domain alone, which is important for p53 association, also leads to an increase, though to a lesser extent, of p53 transcriptional activity (Figure 7B). However, no further increase in p53 transcriptional activity could be observed when we co-transfected WT *PTEN* with *p53ΔC*, an active form of p53

that lacks the PTEN binding domain, into p53-deficient SAOS2 cells (Figure 7C). These results suggest that the regions responsible for the physical association between PTEN and p53 are crucial for PTEN's function in controlling p53 protein stability (Figure 4A) as well as its transcriptional activity (Figures 7B and 7C).

Since PTEN controls G1-S transition and cell death through pathways overlapping with those controlled by p53, we are limited by the measurable biological effects that are solely dependent on p53 function and not influenced by PTEN status.

A

B

C

D

Figure 7. PTEN controls p53 transcriptional activity

For comparison, luciferase activity from each experiment was normalized to that of WT cells and presented as a percentage of increase. Three independent tests were performed for each experiment and the mean ± SD was presented here.

A: p53 transcriptional activity is reduced in $Pten^{\Delta loxp/\Delta loxp}$ null MEF cells. LMB treatment can restore p53 protein levels (right panel) but not its transcriptional activity (left panel) in $Pten^{\Delta loxp/\Delta loxp}$ null MEF cells. Cells were transfected with pRGCE4Luc and p53 transcriptional activity was measured 24 hr post transfection. For LMB treatment, cells were treated with 10 μM LMB for 12 hr prior to each experiment.

B: p53 transcriptional activity can be restored by reintroducing the wild-type (W), CS mutant (CS), or C2 fragment (C2) of PTEN into the $Pten^{\Delta loxp/\Delta loxp}$ MEF cells.

C: PTEN has no effects on the transcriptional activity of the C-terminal deleted p53-ΔC, which lacks PTEN binding domain.

D: p21 transcriptional activation by the endogenous p53 in response to UV irradiation is partially impaired in $Pten^{\Delta loxp/\Delta loxp}$ null MEF cells. Sub-confluent MEF cells were irradiated with 50 J/m^2 of UV. Twelve hours post irradiation, p21 mRNA levels were measured by Northern blot analysis (left panel) and the fold-of-increase after UV treatment was quantified and presented (right panel).

To demonstrate the biological consequence of *Pten* deletion on p53 functions, we measured the endogenous p21 mRNA levels in response to DNA damage. p21 is an immediate downstream target gene for p53 transcriptional activity although p21 mRNA levels can be regulated by both p53-dependent and -independent mechanisms. Importantly, no literature has indicated that p21 transcriptional activation in response to UV treatment is controlled by the PTEN/PI3K/AKT pathway. As shown in Figure 7D, in response to UV irradiation, p21 mRNA levels are significantly increased in the WT MEFs; $p53^{+/-}$ cells are less responsive and *p53* null cells are completely nonresponsive. Even though the basal mRNA level of p21 is not influenced by *Pten* status, its response to UV irradiation is impaired in *Pten* null cells (Figure 7D, right). Note the fold p21 mRNA increase in *Pten* null cells falls between $p53^{+/-};Pten^{+/+}$ and $p53^{-/-};Pten^{+/+}$ cells, which fits well with the endogenous p53 function. These results indicate that the endogenous p53 transcriptional activity is indeed controlled by the PTEN tumor suppressor.

PTEN controls p53 transcription activity by modulating its DNA binding

Several proteins have been shown to interact with the p53 C-terminal domain and enhance p53 DNA binding by relieving the C-terminal inhibitory effect (Jayaraman et al., 1997a; Nie et al., 2000). This prompted us to measure the possible effect of PTEN on p53 DNA binding activity. Both WT PTEN and the PTEN-C2 (PTEN-C) fragment markedly enhanced the DNA binding activity of WT p53 (Figure 8A, left panel, comparing lane 2 and lanes 3–6), similar to activation of p53 by c-Abl (lanes 14 and 15). Consistent with our domain mapping studies, the PTEN-CT domain, which has weaker binding affinity to p53 (Figure 6B), also has less effect on p53 DNA binding activity (lanes 7 and 8). Furthermore, PTEN had no effect on the DNA binding activity of the C-terminal truncated form of p53 (p53-ΔC), which lacks the PTEN association domain (Figure 8A, right panel, comparing lane 4 and lanes 5–7).

To show that PTEN can bind to p53 and enhance its DNA binding activity in vivo, we performed a chromatin immunoprecipitation analysis (ChIP) using the p21 promoter as a target. Both *WT PTEN* and *PTEN-CS* increase the binding activity of the endogenous p53 to the p21 promoter by 2.5-fold (Figure 8B). To further test the significance of the PTEN-p53 interaction on this activation, we performed the ChIP assay by co-transfecting *PTEN* with either WT p53 or *p53-ΔC* mutant that is defective in PTEN interaction (Figure 6B). Similar to their effects on the endogenous p53, WT PTEN and PTEN-CS were able to increase the DNA binding activity of transfected p53 to the p21 promoter by 2.5-fold (Figure 8C). In contrast, neither WT PTEN nor PTEN-CS had any significant effect on the binding activity of p53-ΔC (Figure 8C). These data suggest that PTEN regulates p53 transcriptional activity, at least in part, by modulating its DNA binding activity. This modulation depends on the physical interaction of PTEN and p53.

Discussion

A major portion of the PTEN literature focuses on the function of PTEN as a lipid phosphatase, and its antagonism of the PI3 kinase pathway. AKT phosphorylation/activation is generally regarded as the hallmark for *PTEN* mutation. In this study, we define a novel role of PTEN as a tumor suppressor: PTEN controls p53 protein levels and transcriptional activity in vivo, and PTEN exerts its role through both phosphatase-dependent and -independent mechanisms. We also provide in vivo evidence for PTEN function inside of the nucleus, which has not been demonstrated before.

Our initial studies rely on mice carrying mutations in the endogenous gene encoding either *p53* or *Pten* to avoid potential side effects caused by overpression of mutant proteins in a tissue culture system. We hypothesized, based on the genetic data from $p53^{+/-};Pten^{+/-}$ heterozygous mice, that PTEN may control p53 protein levels. This hypothesis was confirmed by measuring the endogenous p53 protein levels in isogenic $Pten^{+/+}$ and $Pten^{-/-}$ ES cells, MEF cells, and brain tissues, as well as by measuring the half-life of p53 in the presence and absence of the endogenous PTEN proteins. These results provide genetic proof for PTEN's role in controlling p53 function. Our study, together with those of others (Mayo et al., 2002; Mayo and Donner, 2001; Ogawara et al., 2002; Zhou et al., 2001), may also help to explain why concomitant mutations in both *p53* and *PTEN* loci are not common. PTEN plays an important role in regulating p53 protein levels and activity; loss of PTEN may decrease the selective pressure on tumors to lose p53 during cancer progression.

In an attempt to further delineate the functional domains responsible for PTEN-mediated p53 stabilization, we discovered a critical role of phosphatase-independent activity of PTEN in regulating p53 protein levels and transcriptional activity. This conclusion is based on (1) reintroduction of *PTEN* phosphatase-dead mutants as well as the *PTEN-C2* region, which lack the phosphatase domain, into $Pten^{\Delta loxp/\Delta loxp}$ cells partially rescues the endogenous p53 protein levels (Figure 4A) and transcriptional activity (Figure 7B); (2) PTEN increases p53 protein levels and prolongs the half-life of p53 in the absence of MDM2 (Figures 4C and 4D). Since MDM2 is a key mediator for PI3K/AKT-controlled p53 degradation, as suggested by previous studies, this result indicates that PTEN can control p53 half-life independently of PI3K/AKT/MDM2 via a currently unknown mechanism; (3) physical interaction of PTEN and p53 is crucial for maximum p53 transcriptional activity (Figure 7), especially for its DNA binding activity (Figure 8).

We by no means imply that the regulation of the PI3K/AKT pathway is not an important part of PTEN's function in controlling tumor formation. The fact that naturally occurring mutations in the PTEN phosphatase domain (such as PTEN-C124S and PTEN-G129E mutants) are tumor causing indicates that the effects of PTEN's phosphatase-independent activity in tumorigenesis may be more tissue specific or associated with a more aggressive phenotype upon loss of PTEN function. However, our data argue strongly that phosphatase-independent mechanisms are important parts of PTEN's biological functions. Notably, some recent studies suggest that activation of AKT alone, such as overexpression of a constitutively activated form of AKT in transgenic mice, cannot account for all of the phenotypes related to PTEN loss (Ackler et al., 2002; Malstrom et al., 2001; Schwertfeger et al., 2001). In *Drosophila*, phenotypes caused by *dPTEN* mutation are not completely covered by *Dp110* or insulin-signaling mutants (Goberdhan et al., 1999), suggesting PTEN may have a broader role than only antagonizing PIP3. Similarly, mutating the putative PIP2 motif in the N-terminal region of PTEN led to loss of PTEN membrane association and failure to rescue the PTEN null phenotype in a

Figure 8. PTEN controls p53 transcriptional activity by modulating its DNA binding activity

A: Electrophoretic mobility shift assay shows that PTEN enhances p53 DNA binding activity. Left panel, p53 DNA binding activity can be significantly enhanced by wild-type PTEN (PTEN, lanes 3 and 4) and PTEN-C2 fragment (PTEN-C, lanes 5 and 6). PTEN-C2 domain with the C-terminal tail (PTEN-CT, lanes 7 and 8) also stimulates p53 DNA binding but to a lesser extent. As a positive control, c-Abl can significantly increase the p53 DNA binding activity (Lane 14). Right panel, DNA binding activity of p53ΔC, which lacks PTEN association domain, is not affected by the presence of PTEN (comparing lanes 4 and 5–7).
B: ChIP analysis. Both WT PTEN and PTEN-CS activate endogenous p53 DNA binding on the p21 promoter. PCR analyses (using primers to p21) on input DNA or α-p53 immunoprecipitated DNA are shown.
C: PTEN enhances DNA binding activity of WT p53, but not mutated p53ΔC in SAOS2 cells. Cells were transfected with the plasmid combination listed below. The DNA binding activity of p53 and p53ΔC on the p21 promoter was analyzed using a ChIP assay. The fold-of-increase in the present of PTEN was quantified and presented in the Supplemental Figure S3 (see *Cancer Cell* website).

chemoattractive response in *Dictyostelium discoideum* (Iijima and Devreotes, 2002).

Several important issues raised by the current study are worth further investigation. First, we have defined the C2 domain as a critical region involved in PTEN/p53 association and PTEN-controlled p53 function. However, since a PTEN mutant that lacks the PTEN-C2 domain is unstable (Maehama et al., 2001; Simpson and Parsons, 2001), we cannot rule out that other regions of the PTEN molecule may contribute to PTEN/p53 complex formation. Second, it would be interesting to provide a mechanistic explanation as to why we cannot observe the PTEN/p53/MDM2 triple complex in vivo (Figure 5A) or MDM2 competing with PTEN in forming complex with p53 in vitro (see Supplemental Figure S2 on *Cancer Cell* website). We hypothesize that the association of PTEN with the C-terminal negative-regulatory domain of p53 may trigger a conformational change in the p53 molecule, thereby preventing MDM2 binding, al-

though we have not yet obtained any conclusive results (data not shown). We also noted that PTEN does not affect p53-DNA complex migration significantly (Figure 8A). The PTEN-stimulated p53-DNA complex could be supershifted by the addition of anti-p53 antibody but not by the addition of anti-PTEN antibody, suggesting that PTEN may not be a part of the p53-DNA complex (data not shown). Similar results were also reported with other proteins, such as c-Abl (Nie et al., 2000) and Ref-1 (Jayaraman et al., 1997b), which interact with the C terminus of p53 and enhance p53 DNA binding. Two explanations may account for this result: first, PTEN may dissociate from the p53-DNA complex during the electrophoresis; second, PTEN may induce a conformational change of latent p53 and dissociate from p53 once bound to DNA. Nevertheless, the ability of PTEN to interact with p53 correlates well with its ability to enhances p53 DNA binding in vitro (Figure 8A) and in vivo (Figures 8C), which supports the view that the interaction plays an

important role in p53 activation. Additionally, further in vivo investigation is required to understand how the dynamics and stoichiometry of the PTEN/p53 complex formation are controlled and altered in cancers.

Similar genetic approaches have been taken by others to address the potential interaction between PTEN and other tumor suppressor genes and oncogenes. *Pten* heterozygous mice have been crossed to Ink4a/ARF (You et al., 2002) and p27 (Di Cristofano et al., 2001) deficient mice, as well as transgenic mice expressing Wnt-1 (Li et al., 2001) or T$_{121}$, a truncated SV40 T antigen which specifically inactivates the pRb family (Xiao et al., 2002). By removing one functional allele of *Pten*, the latencies of tumor formation are significantly reduced in these animals. These compound heterozygous mice, together with the one we have generated in this study, also provide opportunities to investigate the interplay between different signaling pathways in tumor initiation, progression, and metastasis.

Taken together, our study provides both genetic and biochemical evidence that the PTEN tumor suppressor regulates the function of p53 by both phosphatase-dependent and -independent mechanisms. Our study may reveal a novel mechanism by which the loss of PTEN can functionally control "two" hits in the course of tumor development by concurrently modulating PI3K and p53 activities. Thus, p53 may play an important role in the initiation of tumorigenesis by mutations in the *PTEN* tumor suppressor gene, and therapies designed to target both PTEN and p53 or their controlled pathways may be beneficial for those cancers genetically marked as PTEN null and p53 WT.

Experimental procedures

Immortalization of MEF cells
Primary MEF cells were harvested from embryonic day 14 embryos with indicated genotype. Independent immortalized MEF lines were established using the 3T9 protocol (Kamijo et al., 1997). To derive *Pten*$^{\Delta loxp/\Delta loxp}$ (Δ/Δ) cells, immortalized *Pten*$^{loxp/loxp}$ (*L/L*) cells, which were positive for *Pten* and *p53* expressions, were transiently transfected with pTurbo-Cre (ES Cell Center, Washington University, St Louis, Missouri) using Effectene transfection reagent (Qiagen) following recommended protocols. Individual colonies were expanded and tested for *Pten* deletion by both PCR and Western blot analysis (Lesche et al., 2002), and approximately 30% of these clones had the exon 5 of the *Pten* gene deleted.

Cell culture and transfection
MEF and SAOS2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM Gibco) supplemented with 10% fetal calf serum (FCS Hyclone), 100 U/ml penicillin and streptomycin (Gibco). To reintroduce PTEN-WT, CS, and GR mutants, or PTEN-C2 domain into *Pten*$^{\Delta/\Delta}$ cells, the above plasmids were cotransfected with a CMV-EGFP vector. GFP-positive cells were then FACS sorted and analyzed as described. U2OS cells were cultured in McMoy's 5A supplemented with 10% FCS. Cell transfection was performed using lipofectAMINE (Invitrogen) or calcium phosphate method. Cells were lysed 28 hr post transfection for protein and luciferase activity measurements.

Western blot analysis and immunoprecipitation
Whole-cell extract was prepared by lysing the cells in a buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.25% Na Deoxycholate, 1 mM DTT, 2 μg/ml aprotinin, and 2 μg/ml leupeptin. Brain tissue was disrupted using a Sonic Dismembrator in buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.25% Na Deoxycholate, 1 mM DTT, 2 μg/ml aprotinin, and 2 μg/ml leupeptin. Cell lysates from each transfection were subjected to SDS-PAGE followed by Western blot analysis using anti-p53 (DO.1, Pab-240, Santa Cruz, FL-393-G, Santa Cruz), PTEN (9552, Cell Signaling Technologies), MDM2 (SMp14, Santa Cruz, Ab-2, Oncogene Research Products), or Vinculin (VIN-11-5, Sigma) or Actin (A 4700, Sigma) antibodies, respectively.

For immunoprecipitation experiments, 500 μg of cell lysate was incubated 12 hr at 4°C with 1 μg antibody (p53 Ab-4, Oncogene Research products; or PTEN antibody 9552, Cell Signaling Technology) plus 50 μl Protein A agarose beads (Immobilized Protein A, Pierce). Beads were washed three times with lysis buffer and centrifuged for 5 min at 5000 g between each wash. Protein was eluted from the beads with 50 μl of 2× Laemmli sample buffer (Bio-Rad). Lysates were separated on a 10% SDS-PAGE gel and transferred onto nitrocellulose (Bio-Rad) using a Semi-Dry TransBlot blotter (Bio-Rad).

For half-life experiments, *Pten*$^{\Delta loxp/\Delta loxp}$ cells and *Pten*$^{loxp/loxp}$ cells were grown to 70% confluence and transferred to serum-free medium containing 50 μg/ml cyclohexamide (Cyclohexamide, high purity, Calbiochem). For *p53*$^{-/-}$*;Mdm2* MEF cells, p53 or p53 and PTEN were transfected 24 hr prior to the addition of 50 ug/ml cyclohexamide in serum free medium. Cells were then lysed at indicated time points and further analyzed by Western blot. To evaluate the role of PI3 kinase pathway in PTEN controlled p53 protein levels, cells were pre-treated with 50 nM wortmannin for 10 min and then proceeded to half-life study in the presence of wortmannin as described above.

Northern blot analysis
Total RNA was purified from 1×10^6 of *Pten*$^{\Delta loxp/\Delta loxp}$ or *Pten*$^{loxp/loxp}$ cells using an RNeasy kit (Qiagen). Fifteen micrograms of total RNA was loaded onto a 1% agarose gel containing 5.4% formaldehyde. RNA was transferred to Hybond-N+ nitrocellulose membrane (Amersham) and probed using standard methods. Quantitation was performed with Image Quant (Molecular Dynamics).

Immunohistochemistry
Immunohistochemical analysis was performed on formalin-fixed paraffin sections following antigen retrieval (BioGenex). PTEN antibody (26H9, Cell Signaling Technology), VECTASTAIN ABC Kit (Mouse IgG, 1:200, Vector Laboratories), and AEC (3-amino-9-ethylcarbazole) substrate (BioGenex) were used for detection according to the recommended protocol.

Transcriptional activation assay
The transcriptional activity of p53 was measured using pRGCE4Luc which contains one copy of the RGC p53 binding site cloned upstream of the adenovirus E4 TATA box and luciferase gene. Cells were lysed 24 hr post transfection in passive lysis buffer in accordance with the Dual-Glo Luciferase Assay System (Promega). Samples were normalized using Renilla Luciferase. Cells treated with LMB (10 μM) were lysed 12 hr post LMB addition.

Electrophoretic mobility shift assay (EMSA)
EMSA was carried out as described (Nie et al., 2000). Briefly, the RGC p53 binding site probe (5′-AGCTTGCCTCGAGCTTGCCTGGACTTGCCTGGT CGACGC-3′) was ^{32}P-labeled with the Klenow fragment. Binding reactions contained 200 cpm of ^{32}P-labeled probe, 75 ng of wild-type p53, or 10 ng of p53ΔC (Δ363), in the presence of 50 or 100 ng of GST-PTEN, GST-PTEN-C, GST-PTEN-CT, GST, or GST-c-Abl, in a total volume of 12.5 μl of reaction buffer (60 mM KCl, 12% glycerol, 5 mM MgCl$_2$, 1 mM EDTA, 1 μg BSA, 0.1 μg poly [d(GC)]). Reactions were incubated at 30°C for 30 min, and then analyzed on a 5% polyacrylamide gel containing 0.5 × TBE (0.045 mM Tris-borate, 0.045 mM sodium borate, 0.001 mM EDTA [pH 8.0]). DNA-protein complexes were visualized with a PhosphorImager using Adobe Photoshop software.

GST pulldown assay
The p53 N-terminal and C-terminal deletion mutants were synthesized according to conditions recommended by the manufacturer (Promega). The mRNAs were translated in vitro for 1.5 hr at 30°C in rabbit reticulocyte lysate in the presence of ^{35}S-methionine. Bacterially expressed GST-PTEN or PTEN-CS was incubated for 60 min with Glutathione-Sepharose (Pharmacia) in lysis buffer (20 mM Tris-borate [pH 8.0], 150 mM NaCl, 1% Triton X-100, 10% Glycerol, 2 mM EDTA, 2 mM DTT, 2 μg/ml Aprotinin, 2 μg/ml Leupeptin. 0.5 mM PMSF). Beads were then incubated for 60 min with the ^{35}S-methionine labeled p53 mutants in incubation buffer (20 mM HEPES [pH 7.4], 150 mM KCl, 0.1% Triton X-100, 10% Glycerol, 0.1 mg/ml BSA, 5 mM EDTA, 5 mM DTT, 4 μg/ml Aprotinin, 4 μg/ml Leupeptin, 1 mM PMSF) with constant mixing. After incubation, the beads were washed three times

with incubation buffer and boiled in 15 μl of 2× SDS sample buffer. The bound proteins were analyzed by SDS-PAGE and ³⁵S-labeled proteins were visualized by autoradiography. The PTEN deletion mutants were constructed by PCR amplification and expressed as GST fusion proteins. Binding to p53 was measured by incubation with in vitro translated p53 or p53-ΔC363 in the conditions as described above.

Chromatin-immunoprecipitation (ChIP) analysis

ChIP analysis was carried out as described (Ma et al., 2001), except that the anti-p53 (FL-393-G, Santa Cruz) antibody was used for immunoprecipitation. After reversing the formaldehyde crosslinking by heating at 65°C overnight, DNA was extracted with phenol/chloroform, precipitated with ethanol, and dissolved in a total of 50 μl TE buffer. PCR amplifications were performed with 2 μl of DNA, using 25 and 30 cycles for SAOS2 and U2OS cells, respectively. Primers used in PCR were 5′-GTGGCTCTGATTGGCTTTCTG-3′ (forward) and 5′-CTGAAAACAGGCAGCCCAAG-3′ (reverse). PCR products were resolved by agarose-gel electrophoresis and visualized by ethidium bromide staining.

The amounts of plasmids transfected into U2OS cells by lipofectAMINE (Invitrogen) were as follows: 4 μg of pMX-IES-gfp-PTEN, 4 μg of pMX-IES-gfp-PTEN-CS. The amounts of plasmids transfected into SAOS2 cells by Effectene (Qiagen) were as follows: 0.4 μg of pCDNA-p53, 0.4 μg of pCDNA-p53ΔC, 2 μg of p21p (a gift from Dr. Xiao-Fan Wang), 4 μg of pMX-IES-gfp-PTEN, 4 μg of pMX-IES-gfp-PTEN-CS.

References

Ackler, S., Ahmad, S., Tobias, C., Johnson, M.D., and Glazer, R.I. (2002). Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene *21*, 198–206.

Bargonetti, J., and Manfredi, J.J. (2002). Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. *14*, 86–91.

Di Cristofano, A., and Pandolfi, P.P. (2000). The multiple roles of PTEN in tumor suppression. Cell *100*, 387–390.

Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P.P. (1998). Pten is essential for embryonic development and tumour suppression. Nat. Genet. *19*, 348–355.

Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi, P.P. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. *27*, 222–224.

Downward, J. (1998). Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. *10*, 262–267.

Franke, T.F., Kaplan, D.R., Cantley, L.C., and Toker, A. (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science *275*, 665–668.

Freedman, D.A., and Levine, A.J. (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. *18*, 7288–7293.

Fujisawa, H., Reis, R.M., Nakamura, M., Colella, S., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2000). Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab. Invest. *80*, 65–72.

Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M., and Wilson, C. (1999). Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. *13*, 3244–3258.

Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A., Zack, J.A., Kornblum, H.I., Liu, X., and Wu, H. (2001). Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science *294*, 2186–2189.

Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell *100*, 57–70.

Hill, M., and Hemmings, B. (2002). Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. *93*, 243–251.

Iijima, M., and Devreotes, P. (2002). Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell *109*, 599–610.

Jayaraman, L., Freulich, E., and Prives, C. (1997a). Functional dissection of p53 tumor suppressor protein. Methods Enzymol. *283*, 245–256.

Jayaraman, L., Murthy, K.G., Zhu, C., Curran, T., Xanthoudakis, S., and Prives, C. (1997b). Identification of redox/repair protein Ref-1as a potent activator of p53. Genes Dev. *11*, 558–570.

Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G., and Sherr, C.J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell *91*, 649–659.

Kato, H., Kato, S., Kumabe, T., Sonoda, Y., Yoshimoto, T., Han, S.Y., Suzuki, T., Shibata, H., Kanamaru, R., and Ishioka, C. (2000). Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res. *6*, 3937–3943.

Koul, A., Willen, R., Bendahl, P.O., Nilbert, M., and Borg, A. (2002). Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer *94*, 2369–2379.

Kurose, K., Gilley, K., Matsumoto, S., Watson, P., Zhou, X.-P., and Eng, C. (2002). Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. *32*, 355–357.

Lee, J.O., Yang, H., Georgescu, M.M., Di Cristofano, A., Maehama, T., Shi, Y., Dixon, J.E., Pandolfi, P., and Pavletich, N.P. (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell *99*, 323–334.

Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Sun, H., Liu, X., and Wu, H. (2002). Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis *32*, 148–149.

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science *275*, 1943–1947.

Li, J., Simpson, L., Takahashi, M., Miliaresis, C., Myers, M.P., Tonks, N., and Parsons, R. (1998). The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. *58*, 5667–5672.

Li, Y., Podsypanina, K., Liu, X., Crane, A., Tan, L.K., Parsons, R., and Varmus, H.E. (2001). Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol. Biol. *2*, 2.

Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. *16*, 64–67.

Ma, H., Baumann, C.T., Li, H., Strahl, B.D., Rice, R., Jelinek, M.A., Aswad, D.W., Allis, C.D., Hager, G.L., and Stallcup, M.R. (2001). Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Curr. Biol. *11*, 1981–1985.

Macleod, K.F., and Jacks, T. (1999). Insights into cancer from transgenic mouse models. J. Pathol. *187*, 43–60.

Maehama, T., and Dixon, J.E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. *273*, 13375–13378.

Maehama, T., Taylor, G.S., and Dixon, J.E. (2001). PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu. Rev. Biochem. *70*, 247–279.

Malstrom, S., Tili, E., Kappes, D., Ceci, J.D., and Tsichlis, P.N. (2001). Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl. Acad. Sci. USA *98*, 14967–14972.

Marsh, D.J., Dahia, P.L., Coulon, V., Zheng, Z., Dorion-Bonnet, F., Call, K.M., Little, R., Lin, A.Y., Eeles, R.A., Goldstein, A.M., et al. (1998). Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22–23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer *21*, 61–69.

Mayo, L.D., and Donner, D.B. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA *98*, 11598–11603.

Mayo, L., and Donner, D. (2002). The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. *27*, 462–467

Mayo, L.D., Dixon, J.E., Durden, D.L., Tonks, N.K., and Donner, D.B. (2002). PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. *277*, 5484–5489.

Myers, M.P., and Tonks, N.K. (1997). PTEN: sometimes taking it off can be better than putting it on. Am. J. Hum. Genet. *61*, 1234–1238.

Myers, M.P., Pass, I., Batty, I.H., Van der Kaay, J., Stolarov, J.P., Hemmings, B.A., Wigler, M.H., Downes, C.P., and Tonks, N.K. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA *95*, 13513–13518.

Nelen, M.R., van Staveren, W.C., Peeters, E.A., Hassel, M.B., Gorlin, R.J., Hamm, H., Lindboe, C.F., Fryns, J.P., Sijmons, R.H., Woods, D.G., et al. (1997). Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. *6*, 1383–1387.

Nie, Y., Li, H.H., Bula, C.M., and Liu, X. (2000). Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol. Cell. Biol. *20*, 741–748.

Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., and Gotoh, Y. (2002). Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. *277*, 21843–21850

Podsypanina, K., Ellenson, L.H., Nemes, A., Gu, J., Tamura, M., Yamada, K.M., Cordon-Cardo, C., Catoretti, G., Fisher, P.E., and Parsons, R. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA *96*, 1563–1568.

Rasheed, B.K., Stenzel, T.T., McLendon, R.E., Parsons, R., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Bigner, S.H. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. *57*, 4187–4190.

Schwertfeger, K.L., Richert, M.M., and Anderson, S.M. (2001). Mammary gland involution is delayed by activated Akt in transgenic mice. Mol. Endocrinol. *15*, 867–881.

Sheng, X., Koul, D., Liu, J.L., Liu, T.J., and Yung, W.K. (2002). Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. Biochem. Biophys. Res. Commun. *292*, 422–426.

Simpson, L., and Parsons, R. (2001). PTEN: life as a tumor suppressor. Exp. Cell Res. *264*, 29–41.

Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., and Mak, T.W. (2001). Regulation of PTEN transcription by p53. Mol. Cell *8*, 317–325.

Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., Siderovski, D.P., and Mak, T.W. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell *95*, 29–39.

Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. *15*, 356–362.

Stiles, B., Gilman, V., Khanzenzon, N., Lesche, R., Li, A., Qiao, R., Liu, X., and Wu, H. (2002). Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol. Cell. Biol. *22*, 3842–3851.

Stocker, H., Andjelkovic, M., Oldham, S., Laffargue, M., Wymann, M.P., Hemmings, B.A., and Hafen, E. (2002). Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science *295*, 2088–2091.

Sun, H., Lesche, R., Li, D.M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., and Wu, H. (1999). PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA *96*, 6199–6204.

Suzuki, A., de la Pompa, J.L., Stambolic, V., Elia, A.J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., et al. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. *8*, 1169–1178.

Wu, X., Senechal, K., Neshat, M.S., Whang, Y.E., and Sawyers, C.L. (1998). The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA *95*, 15587–15591.

Xiao, A., Wu, H., Pandolfi, P.P., Louis, D.N., and Van Dyke, T. (2002). Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell *1*, 157–168.

Yamada, K.M., and Araki, M. (2001). Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. *114*, 2375–2382.

You, M.J., Castrillon, D.H., Bastian, B.C., O'Hagan, R.C., Bosenberg, M.W., Parsons, R., Chin, L., and DePinho, R.A. (2002). Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. USA *99*, 1455–1460.

Zhou, B.P., and Hung, M.C. (2002). Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin. Oncol. *29*, 62–70.

Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M.C. (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. *3*, 973–982.